VÃ©ronique A Dartois

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2141073/publications.pdf

Version: 2024-02-01

169 papers	13,345 citations	28274 55 h-index	27406 106 g-index
179 all docs	179 docs citations	179 times ranked	12766 citing authors

#	Article	IF	Citations
1	The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Reviews Microbiology, 2009, 7, 845-855.	28.6	1,179
2	Spiroindolones, a Potent Compound Class for the Treatment of Malaria. Science, 2010, 329, 1175-1180.	12.6	1,031
3	Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis. New England Journal of Medicine, 2012, 367, 1508-1518.	27.0	496
4	The association between sterilizing activity and drug distribution into tuberculosis lesions. Nature Medicine, 2015, 21, 1223-1227.	30.7	387
5	Spirotetrahydro Î²-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria. Journal of Medicinal Chemistry, 2010, 53, 5155-5164.	6.4	381
6	The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nature Reviews Microbiology, 2014, 12, 159-167.	28.6	328
7	An adenosine nucleoside inhibitor of dengue virus. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20435-20439.	7.1	323
8	Tryptophan Biosynthesis Protects Mycobacteria from CD4 T-Cell-Mediated Killing. Cell, 2013, 155, 1296-1308.	28.9	296
9	Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunological Reviews, 2015, 264, 288-307.	6.0	287
10	Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nature Medicine, 2016, 22, 531-538.	30.7	273
11	A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nature Communications, 2010, 1, 57.	12.8	250
12	High-Sensitivity MALDI-MRM-MS Imaging of Moxifloxacin Distribution in Tuberculosis-Infected Rabbit Lungs and Granulomatous Lesions. Analytical Chemistry, 2011, 83, 2112-2118.	6.5	235
13	Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis. Nature Microbiology, 2017, 2, 17072.	13.3	222
14	ClpP ofBacillus subtilisis required for competence development, motility, degradative enzyme synthesis, growth at high temperature and sporulation. Molecular Microbiology, 1998, 27, 899-914.	2.5	210
15	Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis, 2012, 92, 453-488.	1.9	193
16	NTM drug discovery: status, gaps and the way forward. Drug Discovery Today, 2018, 23, 1502-1519.	6.4	186
17	Immune activation of the host cell induces drug tolerance in <i>Mycobacterium tuberculosis</i> both in vitro and in vivo. Journal of Experimental Medicine, 2016, 213, 809-825.	8.5	169
18	Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	159

#	ARTICLE	IF	CITATIONS
19	Radiologic Responses in Cynomolgus Macaques for Assessing Tuberculosis Chemotherapy Regimens. Antimicrobial Agents and Chemotherapy, 2013, 57, 4237-4244.	3.2	156
20	Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions. Antimicrobial Agents and Chemotherapy, 2012, 56, 446-457.	3.2	154
21	Fatty acid synthesis is required for breast cancer brain metastasis. Nature Cancer, 2021, 2, 414-428.	13.2	147
22	Systemic Antibacterial Activity of Novel Synthetic Cyclic Peptides. Antimicrobial Agents and Chemotherapy, 2005, 49, 3302-3310.	3.2	144
23	Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nature Reviews Microbiology, 2022, 20, 685-701.	28.6	142
24	Tuberculosis drugsâ€™ distribution and emergence of resistance in patientâ€™s lung lesions: A mechanistic model and tool for regimen and dose optimization. PLoS Medicine, 2019, 16, e1002773.	8.4	139
25	Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis. Science Translational Medicine, 2013, 5, 214ra168.	12.4	134
26	Reduced Drug Uptake in Phenotypically Resistant Nutrient-Starved Nonreplicating Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 1648-1653.	3.2	133
27	Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. Journal of Antimicrobial Chemotherapy, 2015, 70, 857-867.	3.0	129
28	Rifabutin Is Active against Mycobacterium abscessus Complex. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	119
29	PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Science Translational Medicine, 2014, 6, 265ra167.	12.4	116
30	Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in <i>Mycobacterium tuberculosis</i> Infected C3HeB/FeJ Mice. ACS Infectious Diseases, 2016, 2, 251-267.	3.8	111
31	Prediction of Drug Penetration in Tuberculosis Lesions. ACS Infectious Diseases, 2016, 2, 552-563.	3.8	110
32	Metronidazole prevents reactivation of latent <i>Mycobacterium tuberculosis</i> infection in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14188-14193.	7.1	109
33	Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 270-277.	3.2	98
34	Phase variation in <i>Mycobacterium tuberculosis glpK</i> produces transiently heritable drug tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19665-19674.	7.1	96
35	A medicinal chemistsâ€™ guide to the unique difficulties of lead optimization for tuberculosis. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4741-4750.	2.2	93
36	Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis. EBioMedicine, 2015, 2, 1627-1633.	6.1	93

#	ARTICLE	IF	CITATIONS
37	Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2008, 62, 713-719.	3.0	92
38	Imidazolopiperazines: Hit to Lead Optimization of New Antimalarial Agents. Journal of Medicinal Chemistry, 2011, 54, 5116-5130.	6.4	91
39	Infection Dynamics and Response to Chemotherapy in a Rabbit Model of Tuberculosis using [¹⁸ F]2-Fluoro-Deoxy- <scp>d</scp> -Glucose Positron Emission Tomography and Computed Tomography. Antimicrobial Agents and Chemotherapy, 2012, 56, 4391-4402.	3.2	89
40	Statin adjunctive therapy shortens the duration of TB treatment in mice. Journal of Antimicrobial Chemotherapy, 2016, 71, 1570-1577.	3.0	87
41	Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isoniazid â€“ Mediated Clearance of Mycobacterium tuberculosis in Rabbit Lungs. PLoS Pathogens, 2011, 7, e1002262.	4.7	83
42	Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis. ACS Infectious Diseases, 2016, 2, 616-626.	3.8	83
43	Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nature Communications, 2019, 10, 4970.	12.8	82
44	Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	79
45	Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against <i>Mycobacterium tuberculosis</i>. ACS Infectious Diseases, 2017, 3, 18-33.	3.8	77
46	Storage lipid studies in tuberculosis reveal that foam cell biogenesis is disease-specific. PLoS Pathogens, 2018, 14, e1007223.	4.7	75
47	The Role of Transport Mechanisms in Mycobacterium Tuberculosis Drug Resistance and Tolerance. Pharmaceuticals, 2012, 5, 1210-1235.	3.8	73
48	Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	73
49	Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives. ACS Infectious Diseases, 2015, 1, 203-214.	3.8	71
50	A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment. Journal of Theoretical Biology, 2015, 367, 166-179.	1.7	68
51	CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis. Nature Microbiology, 2022, 7, 766-779.	13.3	68
52	Efficacy and Safety of Metronidazole for Pulmonary Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 3903-3909.	3.2	67
53	Phenolic Acid-Mediated Regulation of the <i>padC</i> Gene, Encoding the Phenolic Acid Decarboxylase of <i>Bacillus subtilis</i>. Journal of Bacteriology, 2008, 190, 3213-3224.	2.2	65
54	Reagent Precoated Targets for Rapid In-Tissue Derivatization of the Anti-Tuberculosis Drug Isoniazid Followed by MALDI Imaging Mass Spectrometry. Journal of the American Society for Mass Spectrometry, 2011, 22, 1409-1419.	2.8	65

#	Article	IF	Citations
55	Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	65
56	Gut Microbiota Metabolite Indole Propionic Acid Targets Tryptophan Biosynthesis in <i>Mycobacterium tuberculosis</i>. MBio, 2019, 10, .	4.1	63
57	Caseum: a Niche for Mycobacterium tuberculosis Drug-Tolerant Persisters. Clinical Microbiology Reviews, 2020, 33, .	13.6	63
58	Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum. Antimicrobial Agents and Chemotherapy, 2016, 60, 735-743.	3.2	62
59	Mycolic acids as diagnostic markers for tuberculosis case detection in humans and drug efficacy in mice. EMBO Molecular Medicine, 2012, 4, 27-37.	6.9	61
60	Mass spectrometry imaging of levofloxacin distribution in TB-infected pulmonary lesions by MALDI-MSI and continuous liquid microjunction surface sampling. International Journal of Mass Spectrometry, 2015, 377, 699-708.	1.5	60
61	A Sterilizing Tuberculosis Treatment Regimen Is Associated with Faster Clearance of Bacteria in Cavitary Lesions in Marmosets. Antimicrobial Agents and Chemotherapy, 2015, 59, 4181-4189.	3.2	59
62	Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model. EBioMedicine, 2016, 4, 104-114.	6.1	59
63	Rifabutin Is Active against Mycobacterium abscessus in Mice. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	59
64	Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach. PLoS Computational Biology, 2017, 13, e1005650.	3.2	57
65	Visualization of Mycobacterial Biomarkers and Tuberculosis Drugs in Infected Tissue by MALDI-MS Imaging. Analytical Chemistry, 2018, 90, 6275-6282.	6.5	55
66	Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD. ACS Infectious Diseases, 2017, 3, 807-819.	3.8	52
67	Adjunctive Host-Directed Therapy With Statins Improves Tuberculosis-Related Outcomes in Mice. Journal of Infectious Diseases, 2020, 221, 1079-1087.	4.0	51
68	Peptide Deformylase Inhibitors as Potent Antimycobacterial Agents. Antimicrobial Agents and Chemotherapy, 2006, 50, 3665-3673.	3.2	50
69	Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis. PLoS Pathogens, 2018, 14, e1006974.	4.7	50
70	Whole-Cell Screen of Fragment Library Identifies Gut Microbiota Metabolite Indole Propionic Acid as Antitubercular. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	49
71	Repositioning rifamycins for Mycobacterium abscessus lung disease. Expert Opinion on Drug Discovery, 2019, 14, 867-878.	5.0	49
72	Indole Propionic Acid, an Unusual Antibiotic Produced by the Gut Microbiota, With Anti-inflammatory and Antioxidant Properties. Frontiers in Microbiology, 2020, 11, 575586.	3.5	49

#	ARTICLE	IF	CITATIONS
73	Inhibition of Dengue Virus by an Ester Prodrug of an Adenosine Analog. Antimicrobial Agents and Chemotherapy, 2010, 54, 3255-3261.	3.2	48
74	Determination of [¹¹ C]Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice by Using Dynamic Positron Emission Tomography Bioimaging. Antimicrobial Agents and Chemotherapy, 2015, 59, 5768-5774.	3.2	47
75	Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections. Journal of Cystic Fibrosis, 2019, 18, 714-720.	0.7	46
76	Novel Cephalosporins Selectively Active on Nonreplicating <i>Mycobacterium tuberculosis</i>. Journal of Medicinal Chemistry, 2016, 59, 6027-6044.	6.4	45
77	High-resolution mapping of fluoroquinolones in TB rabbit lesions reveals specific distribution in immune cell types. ELife, 2018, 7, .	6.0	45
78	An explant technique for high-resolution imaging and manipulation of mycobacterial granulomas. Nature Methods, 2018, 15, 1098-1107.	19.0	43
79	Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	42
80	KapB is a lipoprotein required for KinB signal transduction and activation of the phosphorelay to sporulation in Bacillus subtilis. Molecular Microbiology, 1997, 26, 1097-1108.	2.5	41
81	In silico evaluation and exploration of antibiotic tuberculosis treatment regimens. BMC Systems Biology, 2015, 9, 79.	3.0	41
82	Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. Science Translational Medicine, 2018, 10, .	12.4	40
83	Dissection of the Functional and Structural Domains of Phosphorelay Histidine Kinase A of Bacillus subtilis. Journal of Bacteriology, 2001, 183, 2795-2802.	2.2	39
84	Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis. Current Clinical Pharmacology, 2010, 5, 96-114.	0.6	39
85	Experimental Tuberculosis in the Wistar Rat: A Model for Protective Immunity and Control of Infection. PLoS ONE, 2011, 6, e18632.	2.5	39
86	Inhibition of Fatty Acid Oxidation Promotes Macrophage Control of Mycobacterium tuberculosis. MBio, 2020, 11, .	4.1	39
87	Structureâ€“Activity Relationships of Antitubercular Nitroimidazoles. 3. Exploration of the Linker and Lipophilic Tail of ((<i>S</i>)-2-Nitro-6,7-dihydro-5<i>H</i>-imidazo[2,1-<i>b</i>][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-Amino PA-824).. Journal of Medicinal Chemistry, 2011, 54, 5639-5659.	6.4	38
88	Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics. Science Translational Medicine, 2021, 13, eabd8077.	12.4	38
89	Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA. MBio, 2018, 9, .	4.1	37
90	Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	37

#	ARTICLE	IF	CITATIONS
91	Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide. Trends in Pharmacological Sciences, 2019, 40, 930-940.	8.7	35
92	TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	34
93	In Vivo-Selected Pyrazinoic Acid-Resistant <i>Mycobacterium tuberculosis</i> Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ACS Infectious Diseases, 2017, 3, 492-501.	3.8	33
94	Imaging and spatially resolved quantification of drug distribution in tissues by mass spectrometry. Current Opinion in Chemical Biology, 2018, 44, 93-100.	6.1	33
95	Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832. Antimicrobial Agents and Chemotherapy, 2021, 65, e0058321.	3.2	33
96	The structureâ€"function relationship of the lipases from Pseudomonas aeruginosa and Bacillus subtilis. Protein Engineering, Design and Selection, 1994, 7, 523-529.	2.1	32
97	Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry (LCM-LC/MS). Journal of Visualized Experiments, 2018, , .	0.3	32
98	Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. Journal of Antimicrobial Chemotherapy, 2018, 73, 1755-1762.	3.0	32
99	The Tuberculosis Drug Accelerator at year 10: what have we learned?. Nature Medicine, 2021, 27, 1333-1337.	30.7	32
100	Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis. Annual Review of Pharmacology and Toxicology, 2021, 61, 495-516.	9.4	30
101	Impact of immunopathology on the antituberculous activity of pyrazinamide. Journal of Experimental Medicine, 2018, 215, 1975-1986.	8.5	29
102	Antitubercular nanocarrier monotherapy: Study of In Vivo efficacy and pharmacokinetics for rifampicin. Journal of Controlled Release, 2020, 321, 312-323.	9.9	29
103	Critical discussion on drug efflux in <i>Mycobacterium tuberculosis</i>. FEMS Microbiology Reviews, 2022, 46, .	8.6	29
104	Indolyl Azaspiroketal Mannich Bases Are Potent Antimycobacterial Agents with Selective Membrane Permeabilizing Effects and in Vivo Activity. Journal of Medicinal Chemistry, 2018, 61, 5733-5750.	6.4	28
105	Both Pharmacokinetic Variability and Granuloma Heterogeneity Impact the Ability of the First-Line Antibiotics to Sterilize Tuberculosis Granulomas. Frontiers in Pharmacology, 2020, 11, 333.	3.5	26
106	Preclinical Evaluation of the Antifolate QN254, 5-Chloro-<i>N</i>â€²6â€²-(2,5-Dimethoxy-Benzyl)-Quinazoline-2,4,6-Triamine, as an Antimalarial Drug Candidate. Antimicrobial Agents and Chemotherapy, 2010, 54, 2603-2610.	3.2	25
107	Evaluation of IL-1 Blockade as an Adjunct to Linezolid Therapy for Tuberculosis in Mice and Macaques. Frontiers in Immunology, 2020, 11, 891.	4.8	25
108	Kasugamycin potentiates rifampicin and limits emergence of resistance in Mycobacterium tuberculosis by specifically decreasing mycobacterial mistranslation. ELife, 2018, 7, .	6.0	25

#	Article	IF	Citations
109	Sequence of the Salmonella typhimurium StyLT1 restriction-modification genes: homologies with EcoP1 and EcoP15 type-III R-M systems and presence of helicase domains. Gene, 1993, 127, 105-110.	2.2	24
110	Targeting protein biotinylation enhances tuberculosis chemotherapy. Science Translational Medicine, 2018, 10, .	12.4	24
111	Alterations in the flow of oneâ€carbon units affect KinBâ€dependent sporulation in Bacillus subtilis. Molecular Microbiology, 1997, 25, 39-51.	2.5	23
112	A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Antimycobacterial Activity. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	23
113	Polyamines Inhibit Porin-Mediated Fluoroquinolone Uptake in Mycobacteria. PLoS ONE, 2013, 8, e65806.	2.5	23
114	NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans. Scientific Reports, 2017, 7, 8853.	3.3	22
115	Novel Pyrimidines as Antitubercular Agents. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	22
116	Investigation of (<i>S</i>)-(âˆ’)-Acidomycin: A Selective Antimycobacterial Natural Product That Inhibits Biotin Synthase. ACS Infectious Diseases, 2019, 5, 598-617.	3.8	22
117	Antitubercular Triazines: Optimization and Intrabacterial Metabolism. Cell Chemical Biology, 2020, 27, 172-185.e11.	5.2	22
118	CinA mediates multidrug tolerance in Mycobacterium tuberculosis. Nature Communications, 2022, 13, 2203.	12.8	22
119	New Evidence for the Complexity of the Population Structure of <i>Mycobacterium tuberculosis</i> Increases the Diagnostic and Biologic Challenges. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1448-1451.	5.6	21
120	High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 4197-4205.	3.2	21
121	Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	20
122	A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA. Cell Chemical Biology, 2020, 27, 560-570.e10.	5.2	20
123	Tissue Distribution of Doxycycline in Animal Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	20
124	Chemicalâ€“genetic interaction mapping links carbon metabolism and cell wall structure to tuberculosis drug efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2201632119.	7.1	20
125	Mycobacterium tuberculosis infection induces hypoxic lung lesions in the rat. Tuberculosis, 2011, 91, 339-341.	1.9	19
126	Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Research, 2017, 19, 107.	5.0	19

#	ARTICLE	IF	CITATIONS
127	Teicoplanin â€" Tigecycline Combination Shows Synergy Against Mycobacterium abscessus. Frontiers in Microbiology, 2018, 9, 932.	3.5	19
128	Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	19
129	An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions. Journal of Visualized Experiments, 2017, , .	0.3	17
130	Therapeutic Potential of Fosmanogepix (APX001) for Intra-abdominal Candidiasis: from Lesion Penetration to Efficacy in a Mouse Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	16
131	Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue. Journal of Experimental Medicine, 2022, 219, .	8.5	16
132	Spectrum of latent tuberculosis â€" existing tests cannot resolve the underlying phenotypes: author's reply. Nature Reviews Microbiology, 2010, 8, 242-242.	28.6	15
133	Pharmacokinetic-Pharmacodynamic Analysis of Spiroindolone Analogs and KAE609 in a Murine Malaria Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 1200-1210.	3.2	15
134	Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in <i>Mycobacterium abscessus</i>. Science Translational Medicine, 2022, 14, eabj3860.	12.4	15
135	Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. Antimicrobial Agents and Chemotherapy, 2022, 66, e0239821.	3.2	15
136	BCG Induces Protection against Mycobacterium tuberculosis Infection in the Wistar Rat Model. PLoS ONE, 2011, 6, e28082.	2.5	14
137	Drug Forgiveness and Interpatient Pharmacokinetic Variability in Tuberculosis. Journal of Infectious Diseases, 2011, 204, 1827-1829.	4.0	14
138	Development and validation of LC-ESI-MS/MS method for analysis of moxifloxacin and levofloxacin in serum of multidrug-resistant tuberculosis patients: Potential application as therapeutic drug monitoring tool in medical diagnosis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1009-1010, 138-143.	2.3	14
139	Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	14
140	Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0067621.	3.2	14
141	Structure, <i>In Vivo</i> Detection, and Antibacterial Activity of Metabolites of SQ109, an Anti-Infective Drug Candidate. ACS Infectious Diseases, 2021, 7, 2492-2507.	3.8	13
142	Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0097821.	3.2	13
143	A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0221221.	3.2	13
144	Identification of Î²-Lactams Active against <i>Mycobacterium tuberculosis</i> by a Consortium of Pharmaceutical Companies and Academic Institutions. ACS Infectious Diseases, 2022, 8, 557-573.	3.8	13

#	Article	IF	Citations
145	Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits. Antimicrobial Agents and Chemotherapy, 2021, 65, e0002421.	3.2	12
146	Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0050621.	3.2	12
147	Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating <i>Mycobacterium tuberculosis</i>. ACS Infectious Diseases, 2019, 5, 1433-1445.	3.8	11
148	A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0151421.	3.2	10
149	Cloning of branched chain amino acid biosynthesis genes and assays of Î±-acetolactate synthase activities in Leuconostoc mesenteroides subsp. cremoris. Research in Microbiology, 1999, 150, 189-198.	2.1	9
150	Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 601-606.	2.2	9
151	Potency boost of a <i>Mycobacterium tuberculosis</i> dihydrofolate reductase inhibitor by multienzyme F ₄₂₀ H ₂ -dependent reduction. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	9
152	Metabolic Imaging through Continuous In Situ Micro-extractions of Tissue Samples via Flowprobe Mass Spectrometry. Current Metabolomics, 2014, 2, 122-131.	0.5	9
153	T Cell Monitoring of Chemotherapy in Experimental Rat Tuberculosis. Antimicrobial Agents and Chemotherapy, 2011, 55, 3677-3683.	3.2	8
154	Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates. European Journal of Pharmaceutical Sciences, 2020, 151, 105421.	4.0	8
155	Potentiation of rifampin activity in a mouse model of tuberculosis by activation of host transcription factor EB. PLoS Pathogens, 2020, 16, e1008567.	4.7	8
156	Bayesian Modeling and Intrabacterial Drug Metabolism Applied to Drug-Resistant <i>Staphylococcus aureus</i>. ACS Infectious Diseases, 2021, 7, 2508-2521.	3.8	8
157	Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0140021.	3.2	8
158	Editorial: NTMâ€”The New Uber-Bugs. Frontiers in Microbiology, 2019, 10, 1299.	3.5	7
159	TB drug susceptibility is more than MIC. Nature Microbiology, 2018, 3, 971-972.	13.3	6
160	Correlative Imaging of Trace Elements and Intact Molecular Species in a Single-Tissue Sample at the 50 Î¼m Scale. Analytical Chemistry, 2021, 93, 13450-13458.	6.5	6
161	On-Slide Heat Sterilization Enables Mass Spectrometry Imaging of Tissue Infected with High-Threat Pathogens Outside of Biocontainment: A Study Directed at <i>Mycobacterium tuberculosis</i>. Journal of the American Society for Mass Spectrometry, 2021, 32, 2664-2674.	2.8	6
162	An optimized method for the detection and spatial distribution of aminoglycoside and vancomycin antibiotics in tissue sections by mass spectrometry imaging. Journal of Mass Spectrometry, 2021, 56, e4708.	1.6	4

#	Article	IF	Citations
163	Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS). European Journal of Medicinal Chemistry, 2022, 232, 114201.	5.5	4
164	Drug concentration at the site of disease in children with pulmonary tuberculosis. Journal of Antimicrobial Chemotherapy, 2022, 77, 1710-1719.	3.0	3
165	A Ginger Root or Plum Model for the Tuberculosis â€œGranulomaâ€?. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 505-507.	5.6	2
166	Kendrick Mass Defect Variation to Decipher Isotopic Labeling in Brain Metastases Studied by Mass Spectrometry Imaging. Analytical Chemistry, 2021, 93, 16314-16319.	6.5	2
167	Effect of C-2 substitution on the stability of non-traditional cephalosporins in mouse plasma. Journal of Antibiotics, 2019, 72, 469-475.	2.0	0
168	DDRE-07. FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS. Neuro-Oncology Advances, 2021, 3, i7-i8.	0.7	0
169	Abstract 90: Fatty acid synthesis is required for breast cancer brain metastasis. , 2021, , .		0